抗胆固醇负担和神经纤维光对痴呆风险的联合影响:上海衰老研究
Danyi Chi1, Xiaoniu Liang2,3,4, Zhenxu Xiao2,3,4
1Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
CNS neuroscience & therapeutics
|December 11, 2025
概括
抗胆固醇药物暴露和高的神经纤维光链 (NfL) 水平独立增加痴呆风险. 两种因素的结合显著提高了痴呆症发病率,突出显示NfL是抗胆固醇性认知脆弱性的关键修饰剂.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗胆固醇药物 (ACD) 与痴呆症有关.
- 神经纤维光链 (NfL) 是神经退行症的一个生物标志物.
- ACD和NfL对痴呆风险的综合影响尚不清楚.
研究的目的:
- 研究抗胆固醇药物暴露与神经退行 (通过NfL测量) 之间的相互作用,以预测痴呆风险.
- 探索NfL作为ACD暴露个体认知脆弱性的修饰者的作用.
主要方法:
- 对1529名没有痴呆症的成年人进行前性队列研究.
- 使用ACB尺度和TSDD量化累积抗胆固醇负担.
- 使用单分子阵列 (Simoa) 测量了血NfL水平.
主要成果:
- 增加的NfL和TSDD暴露独立地与痴呆风险增加有关.
- 暴露在高NfL和TSDD的参与者,累计痴呆发病率大大增加.
- 高TSDD和高NfL一起显著增加痴呆风险 (HR 6.34).
结论:
- 血NfL作为抗胆固醇相关认知脆弱性的关键修饰剂.
- 这些发现为痴呆风险分层提供了机制性见解.
- 支持以生物标志物为指导的抑郁症治疗策略,适用于患有ACD的老年人.
相关概念视频
Pharmacodynamics in Geriatric Patients: Effects of Age
175
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
175
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Dementia
486
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
486
Drug Dosing: Geriatric Patients
209
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
209
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K


